Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

COVID-19-vaccines/Immunosuppressants/Rituximab

Lack of efficacy, COVID-19 and rebound in the form of worsening of pemphigus vulgaris

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Koszegi B, et al. Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia. Frontiers in Medicine 10: no pagination, Jan 2023. Available from: URL: https://journal.frontiersin.org/journal/medicine Koszegi B, et al. Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia. Frontiers in Medicine 10: no pagination, Jan 2023. Available from: URL: https://​journal.​frontiersin.​org/​journal/​medicine
Metadaten
Titel
COVID-19-vaccines/Immunosuppressants/Rituximab
Lack of efficacy, COVID-19 and rebound in the form of worsening of pemphigus vulgaris
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54002-1

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Theophylline

Case report

Methotrexate

Case report

Dronedarone